Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/qjmed/hcaa107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Herpes zoster prevention in multiple sclerosis and neuromyelitis optica spectrum disorders.
Neurol Neurochir Pol
January 2025
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland.
A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society, the Polish Society of Family Medicine, and the Polish Society of Vaccinology has developed a consensus on supplementary data to the recommendations of the expert group of the Polish Society of Vaccinology, the Polish Society of Family Medicine, the Polish Dermatological Society, the Polish Association for the Study of Pain, and the Polish Neurological Society, and ECTRIMS/EAN of 2023 with regard to the currently available in Poland recombinant herpes zoster vaccine (RZV). It is intended for the prevention of herpes zoster and postherpetic neuralgia in individuals aged > 50 and individuals aged ≥ 18 who belong to herpes zoster risk groups. In Poland it is available with 50% reimbursement exclusively for patients aged 65 and older who have an increased risk of developing herpes zoster.
View Article and Find Full Text PDFClinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients.
Sci Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Abassia, Cairo, Egypt.
Some patients with neuromyelitis optica spectrum disorder (NMOSD)-like symptoms test negative for anti-aquaporin-4 (anti-AQP4) antibodies. Among them, a subset has antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a condition now termed MOG antibody-associated disease (MOGAD). MOGAD shares features with NMOSD, like optic neuritis and myelitis, but differs in pathophysiology, clinical presentation, imaging findings, and biomarkers.
View Article and Find Full Text PDFThe epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population.
Ann Clin Transl Neurol
January 2025
Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, Colorado, USA.
Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.
Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin-4 IgG test or (2) any G36 ICD-10 code.
The emerging role of the microglia triggering receptor expressed on myeloid cells (TREM) 2 in multiple sclerosis.
Exp Neurol
February 2025
Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address:
Background: The chronic inflammatory condition known as multiple sclerosis (MS) causes inflammation and demyelination in the central nervous system (CNS). The activation of multiple cell types, including the CNS's resident immune cells called microglia, is a component of the immunological response in MS. Recently, the triggering receptor expressed on myeloid cells (TREM) family has emerged as a crucial player in modulating microglial function and subsequent neuroinflammation.
View Article and Find Full Text PDFCurrent and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review.
JAMA Neurol
January 2025
Department of Neurology, Medical Faculty and University Hospital, Heinrich-Heine University of Düsseldorf, Düsseldorf, Germany.
Article Synopsis
- Advancements in molecular engineering have led to the development of CAR T-cell therapy, showing potential for treating various neurological disorders, including brain tumors and autoimmune conditions.
- Although initial human trials for treating glioblastoma have had limited success, animal studies show promise for other conditions like multiple sclerosis and neuromyelitis optica spectrum disorders.
- Innovative strategies using modified CAR T cells targeting autoreactive B cells are showing potential for treating autoimmune encephalitis, suggesting a hopeful future for CAR T-cell applications in neurology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!